TRIM69 is an E3 ubiquitin ligase with multifaceted roles in antiviral immunity, cell cycle regulation, and cancer suppression. Primary antiviral function: TRIM69 restricts viral infections including dengue virus and HIV by ubiquitinating viral proteins such as dengue NS3 for proteasomal degradation 1, and may act as a pan-antiflaviviral restriction factor 1. Additionally, TRIM69 remodels microtubules through SPRY domain binding to tubulin C-termini, inhibiting dynein-dependent HIV virion migration toward the nucleus 2. Mechanistic roles: TRIM69 ubiquitinates cellular substrates including MST2 (promoting centrosome dynamics and mitotic progression via PLK1 phosphorylation) 3, PRKCD (suppressing gastric cancer anoikis resistance and metastasis) 4, FSP1 (regulating ferroptosis vulnerability in hepatocellular carcinoma) 5, and EYA4 (promoting pancreatic tumorigenesis) 6. TRIM69 also inhibits UVB-induced apoptosis and ROS production by promoting p53 ubiquitination 7. Clinical significance: TRIM69 expression is reduced in multiple cancers (gastric, colon, pancreatic) and inversely correlates with metastasis and unfavorable prognosis 86. Restoring TRIM69 expression represents a potential therapeutic strategy for metastatic cancers and improving immunotherapy sensitivity.